Chris Heery, Arcellx CMO

#AS­CO22: Un­con­cerned with lat­er mar­ket en­try, Ar­cel­lx on the up with new BC­MA CAR-T da­ta

Ar­cel­lx $ACLX has been trad­ing up more than 25% in the last five days, thanks to an AS­CO ab­stract for its Phase I tri­al for its CAR-T ther­a­py for mul­ti­ple myelo­ma. Now, the biotech is ready to re­veal an up­dat­ed pic­ture.

The ex­pand­ed re­sults on its BC­MA-tar­get­ing CAR-T ther­a­py in­clude 31 pa­tients, 16 of which have fol­low-up da­ta for at least one year. Of the 16 pa­tients with 12-month da­ta, 13 showed a com­plete re­sponse to Ar­cel­lx’s ther­a­py — a CR rate of 81%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.